Latest Cancer treatments Stories
A team of researchers at NASA's Johnson Space Center in Houston and Lawrence Berkeley National Laboratory in Berkeley, Calif., has found radiation from protons could further enhance a process that occurs during tumor progression. This information may help lead to better methods to protect astronauts from the harmful effects of radiation in space, as well as help cancer researchers on Earth better understand the effects of radiation treatment on the human body. NASA is particularly...
PARIS and TARRYTOWN, N.Y., Aug. 3, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP(®) (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing...
HOUSTON, Aug. 3, 2012 /PRNewswire-USNewswire/ -- A team of researchers at NASA's Johnson Space Center in Houston and Lawrence Berkeley National Laboratory in Berkeley, Calif., has found radiation from protons could further enhance a process that occurs during tumor progression. This information may help lead to better methods to protect astronauts from the harmful effects of radiation in space, as well as help cancer researchers on Earth better understand the effects of radiation...
ATLANTA, Aug. 3, 2012 /PRNewswire/ -- U.S. News & World Report recently issued its annual list of America's best hospitals, including the country's top-ranked hospitals for cancer. All 50 of these cancer hospitals are users of Elekta solutions, which include advanced information management, treatment planning, brachytherapy and treatment delivery. "Consistently ranking among the best in any care delivery category is testament to the dedication and commitment of a healthcare...
Lawrence LeBlond for redOrbit.com - Your Universe Online In some cancers, doctors find that tumors shrink with treatment, yet only briefly, and then come back with a vengeance. Now, recent studies on three different types of tumors suggest that cancer stem cells are resistant to chemotherapy and radiotherapy and may explain why cancer becomes resistant to treatment. A team of independent researchers came to the realization while studying tumors of the brain, intestines and skin in mice....
SUNNYVALE, Calif., Aug. 2, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that doctors at Instituto Neurologico de Colombia (INDEC) in Medellin, Colombia are now treating patients using the first and only robotic radiosurgery system designed to treat cancerous and non-cancerous tumors anywhere in the body, including the head, spine, lung, prostate, liver and pancreas. INDEC is the first center in South America to...
In the news release, Pharmacyclics® Triggers Significant Milestone Payment and Provides Clinical Program Update, issued 01-Aug-2012 by Pharmacyclics, Inc. over PR Newswire, we are advised by the company that the first paragraph, last sentence, should read "calendar 2012" rather than "calendar 2013" as originally issued inadvertently. The complete, corrected release follows: Pharmacyclics® Triggers Significant Milestone Payment and Provides Clinical Program Update SUNNYVALE,...
SUNNYVALE, Calif., Aug. 1, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the international Phase III randomized, multicenter, open-label clinical trial, RESONATE(TM) (PCYC-1112), of ibrutinib versus ofatumumab for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) initiated by Pharmacyclics has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a $50 million...
NEWARK, N.J., Aug. 1, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Fred Hutchinson Cancer Research Center has become a clinical site for the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML). The trial is designed to establish safety and efficacy of API's drug Actimab-A in AML patients over the age of 60. Actimab-A...
Immunovative, Inc. (“IMUN”) (OTCBB: IMUN) announces today that ImmuNews, a newsletter published by Immunovative, Inc. is now available to the public. ImmuNews is designed to educate and inform our shareholders and followers of happenings in the rapidly developing field of cancer immunotherapy and provide updated information on our progress toward bringing our own products to the market. New York, NY (PRWEB) July 31, 2012 immunovative, Inc. (“IMUN”) (OTCBB: IMUN) announces today...
